William Bell
Family · Loranger, LANPI 1659046258
Payments from drug & device makers
Across 131 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$418
- Lilly USA, LLC$358
- AstraZeneca$352
- Novo Nordisk$286
- GSK$211
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$189
- plus $721 from 23 others
What the payments were for
- Food & beverage$2,535100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $418 |
| Lilly USA, LLC | 24 | $358 |
| AstraZeneca | 5 | $352 |
| Novo Nordisk | 17 | $286 |
| GSK | 6 | $211 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $189 |
| Sanofi-aventis U.S. LLC | 4 | $143 |
| Dexcom, Inc. | 3 | $63 |
| Boehringer Ingelheim | 3 | $51 |
| UCB, Inc. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Pfizer | 2 | $38 |
| Optinose US, Inc. | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Merck | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- TRELEGY ELLIPTA$120
- BREZTRI$115
How this compares
$2,535 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $24,622 |
| TrulicityDulaglutide | 18 | $17,202 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,127 |
| FarxigaDapagliflozin Propanediol | 23 | $14,201 |
| OzempicSemaglutide | 12 | $11,244 |
| EliquisApixaban | 13 | $7,549 |
| LinzessLinaclotide | 13 | $6,869 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,197 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $982 |
| Gabapentin | 35 | $714 |
| Buspirone Hcl | 44 | $598 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $583 |
| Pantoprazole Sodium | 31 | $543 |
| Nateglinide | 12 | $466 |
| Losartan Potassium | 59 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $358 | $41,82442 claims |
| GSKTrelegy Ellipta | $211 | $15,12724 claims |
| AstraZenecaFarxiga | $352 | $14,20123 claims |
| Novo NordiskOzempic | $286 | $11,24412 claims |
| PfizerEliquis | $38 | $7,54913 claims |
| AbbVieLinzess | $418 | $6,86913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.
Other family in Loranger
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.